Testing SXRN injection for cancer-related weight loss
Part of Cancer, Digestive system clinical trials.
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have advanced solid tumor cancer that has spread or cannot be removed
- Have lost at least 5% of your body weight in the last 6 months, or have low appetite or high inflammation
- If you are in the first part of the study, you must have tried standard cancer treatments that no longer work or caused severe side effects
- Be well enough to walk and do daily activities (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called selpercatinib can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight while on chemotherapy. It aims to see if the drug is safe and might reverse or prevent further weight loss.
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This study tests an investigational drug called INB301 to see if it can help cancer patients who have lost significant weight due to their disease. The drug targets a protein involved in appetite and muscle loss.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Hear when a new Cachexia-Anorexia Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.